UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance shows increased expenses and losses, while product development highlights potential growth with new launches and trials. However, the Q&A reveals delays and uncertainties in revenue recognition and adoption, impacting short-term expectations. The lack of clear guidance on demand and revenue timelines, coupled with financial losses, outweighs the positive aspects, leading to a negative sentiment.
Key Financial Performance
JELMYTO net product revenue $25.7 million, representing a 13% increase in underlying demand revenue over the same period in 2024. The increase was driven by both price favorability and volume growth.
ZUSDURI sales $1.8 million during the third quarter of 2025. Preliminary demand revenue estimate for October was $4.5 million, reflecting early momentum in Q4.
Total revenues $27.5 million, consisting of $25.7 million in JELMYTO sales and $1.8 million in ZUSDURI sales.
R&D expenses $14 million in the third quarter of 2025, compared to $11.4 million in the same period in 2024. The increase of $2.6 million was primarily driven by costs associated with the Phase III UTOPIA trial for UGN-103.
Selling, general and administrative expenses $37.6 million in the third quarter of 2025, compared to $28.9 million in the same period in 2024. The increase of $8.7 million was primarily driven by ZUSDURI commercial preparation activities and the expansion of the sales force.
Noncash financing expense $4.6 million in the third quarter of 2025, compared to $5.9 million in the same period in 2024.
Interest expense $3.4 million in the third quarter of 2025, compared to $2.7 million in the same period in 2024. The increase was primarily driven by interest expense related to the third tranche of the loan funded in September 2024.
Net loss $33.3 million or $0.69 per basic and diluted share in the third quarter of 2025, compared to a net loss of $23.7 million or $0.51 per basic and diluted share in the same period in 2024.
Cash, cash equivalents and marketable securities $127.4 million as of September 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZUSDURI: Preliminary demand revenue for October doubled compared to the previous 3 months. Physician enthusiasm is high, and the product addresses a $5 billion annual market. Expected to deliver over $1 billion in peak revenue. Adoption is expected to accelerate with a permanent J-code effective January 1, 2026.
JELMYTO: Net product revenue of $25.7 million in Q3 2025, a 13% increase over the same period in 2024. Continues to demonstrate clinical value and prescriber confidence. Expanded field team to drive further growth.
UGN-103: Phase III UTOPIA study showed a 3-month complete response rate of 77.8%. NDA submission planned for the second half of 2026 with potential approval in 2027.
UGN-301: Phase I study completed, but the program is discontinued due to lack of advancement potential. Resources will be redirected to UGN-103 and UGN-501.
Market Access for ZUSDURI: Achieved broad accessibility through commercial, Medicare, and Medicaid insurance programs, covering over 95% of eligible patients. Nearly 600 sites activated for ZUSDURI.
Sales Force Expansion: Onboarded 30 new sales representatives, bringing the total to 82, with approximately 130 customer-facing professionals supporting ZUSDURI and JELMYTO.
Operational Challenges for ZUSDURI: Delays in patient dosing due to logistical and reimbursement challenges. Efforts underway to streamline workflows and reduce conversion time from patient enrollment to treatment.
Discontinuation of UGN-301: Strategic decision to discontinue UGN-301 program and focus resources on UGN-103 and UGN-501.
UGN-501 Development: IND-enabling studies ongoing with a Phase I trial planned for 2026. Designed to selectively destroy cancer cells and trigger a robust immune response.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
ZUSDURI launch challenges: The uptake of ZUSDURI has been slower than expected due to logistical and operational challenges, including reimbursement concerns with a temporary miscellaneous J-code. This has caused delays in converting patient enrollment forms to actual treatments.
Operational readiness and site activation: Although nearly 600 sites are activated and ready to order and administer ZUSDURI, activation does not necessarily mean patients are being treated. There is a lag of 45-60 days between patient enrollment and dosing, particularly in hospital settings where formulary and P&T approvals extend timelines.
Temporary J-code complexity: The use of a temporary miscellaneous J-code for ZUSDURI has added administrative complexity, particularly for community practices, delaying broader adoption. A permanent J-code will only be available starting January 1, 2026.
High operating expenses: Selling, general, and administrative expenses increased significantly year-over-year, driven by ZUSDURI commercial preparation activities and sales force expansion, which could strain financial resources.
R&D cost pressures: R&D expenses increased due to costs associated with the Phase III UTOPIA trial for UGN-103, adding financial pressure.
Discontinuation of UGN-301 program: The UGN-301 program was discontinued due to an insufficient clinical profile to warrant advancement, representing a setback in the company's pipeline and resource allocation.
Net loss and financial strain: The company reported a net loss of $33.3 million for the third quarter of 2025, an increase from the previous year, indicating ongoing financial challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ZUSDURI Adoption and Revenue Projections: The company expects an acceleration in ZUSDURI adoption once the permanent product-specific J-code goes into effect on January 1, 2026. ZUSDURI addresses an estimated $5 billion annual market, with long-term potential to deliver over $1 billion in peak revenue.
UGN-103 NDA Submission and Approval: The company plans to submit a New Drug Application (NDA) for UGN-103 in the second half of 2026, with potential approval anticipated in 2027.
UGN-501 Phase I Trial: A Phase I trial for UGN-501 in recurrent non-muscle invasive bladder cancer is planned for initiation in 2026.
JELMYTO Revenue Guidance: The company expects 2025 JELMYTO net product revenues to be in the range of $94 million to $98 million, implying year-over-year growth of approximately 8% to 12% over 2024.
Operational Expense Guidance: Full-year 2025 operating expenses are expected to be in the range of $215 million to $225 million, including noncash share-based compensation expense of $11 million to $14 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the specifics on the timing of revenue recording, particularly the observed timing in real-time and the outlook for Q4?
A:The time to treat first patients involves benefit investigation and prior authorizations due to the new therapy. Administrative approvals and site setup also contribute to delays. The observed timing aligns with the anticipated 45-60 days, with gradual improvement expected as practices gain experience, particularly by 2026. For remittance, claims take longer during the miscellaneous J-code period, but this is expected to improve over time. The same dynamics are expected to continue through Q4 and into early 2026.
Q:How much visibility do you have into physicians waiting for the permanent J-code to begin submitting patient enrollment forms?
A:Many physicians, especially in community settings, are waiting for the permanent J-code effective January 1 to prescribe ZUSDURI. The company is preparing these practices during Q4 to ensure readiness for patient enrollment activation in January. There is a list of identified patients, but the demand has not been quantified. The company is prioritizing pulling through patient enrollment forms and ensuring readiness for the new year.
Q:Can you provide color on how patient enrollment forms are tracking month-over-month and clarify the $4.5 million demand revenue estimate?
A:Patient enrollment forms are showing steady month-over-month growth, with weekly averages increasing. The $4.5 million figure represents actual sales, not implied demand. The trend in patient enrollment forms aligns with the revenue growth observed in October, indicating strong demand.
Q:What is the expected impact of the J-code on the lag time between patient enrollment and dosing, and what additional data is needed for UGN-103 approval?
A:The J-code is expected to simplify processes, reduce manual claim submissions, and improve remittance times, leading to faster patient starts. However, the improvement will be gradual, with the goal of reducing the lag time to under 30 days by 2026. For UGN-103, the FDA is expected to require 12 months of follow-up data, including sustained complete response rates, for approval. The company plans to submit in 2026 with approval expected in 2027.
Q:Can the time from enrollment to revenue recognition for ZUSDURI match JELMYTO's timeline by 2026, and will additional capital be needed in 2026?
A:The time from enrollment to revenue recognition for ZUSDURI is expected to converge with JELMYTO's timeline over the course of 2026. The company has $127 million in cash and expects to achieve profitability without additional capital, but remains open to opportunistic funding if needed.
Q:What is the ratio of community uptake versus institutional uptake for ZUSDURI, and how does it compare to JELMYTO?
A:Currently, 35-40% of ZUSDURI patients are treated in the community, with 60-65% in hospitals. This is expected to shift towards more community uptake as the permanent J-code takes effect in 2026. JELMYTO initially had more institutional use but is now evenly split between community and institutional settings.
Q:How long does it take to schedule a TURBT surgery, and what are the financial incentives for urologists to use ZUSDURI instead?
A:Scheduling a TURBT surgery typically takes 4-6 weeks. Urologists earn a few hundred dollars per TURBT surgery, while administering ZUSDURI can be financially positive and allows nurses to handle the procedure, freeing up the urologist's time for other tasks.
Q:What is the competitive landscape for UGN-501, and how does it compare to CG Oncology's asset?
A:UGN-501 is similar to CG Oncology's asset in targeting high-grade non-muscle invasive bladder cancer. UGN-501 is engineered for higher potency, faster replication, and dual mechanisms of tumor cell lysis and immune response. It is in IND-enabling stages with Phase I expected in 2026, and may have applications beyond urologic oncology.
Q:Review of Unclear Management Responses
A:Management avoided directly quantifying the demand from physicians waiting for the J-code, the exact number of patient enrollment forms, and the specific timeline for ZUSDURI's time to revenue recognition matching JELMYTO's. They also provided limited details on the financial impact of UGN-501 compared to competitors.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act sale
CREATES Act
Dr
III UTOPIA
Investor Relations
PEF
PEFs
Pharma
Phase III
RD
RTGel platform
ability
acceleration adoption
adoption patient
application NDA
bill
community practice
conversion
effect
enrollment form
expense noncash
field
formulation grade
generation mitomycin
indicator
intent
manager
minute
noncash share
patient enrollment
patient market
prescribers
site readiness
submission
track
usage
volume
URGN Transcript
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with a 15% revenue increase, driven by JELMYTO and ZUSDURI. Despite net losses, there's improvement due to cost management. Product development is on track, with ZUSDURI and clinical trials progressing as planned. The Q&A session did not reveal significant concerns. However, risks in commercialization and regulatory approvals remain. Overall, the positive financials and strategic focus on growth suggest a likely positive stock reaction, especially given the lack of negative sentiment from analysts.
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary indicates strong product development and market strategy, with ZUSDURI outperforming JELMYTO and expanding into community practices. Despite increased expenses and net loss, the optimistic guidance for ZUSDURI and strategic transition plans to UGN-103 suggest positive future prospects. The Q&A section reinforces confidence in ZUSDURI's growth, despite management's cautious responses. The absence of negative financial surprises and steady product adoption supports a positive sentiment, likely leading to a stock price increase of 2% to 8%.
URGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
